/ /

  • linkedin
  • Increase Font
  • Sharebar

    Innovation in glaucoma thriving

    advances in pharmaceuticals, devices, and diagnostics fueling growth for sector

     

    Aerie Pharmaceuticals

    Aerie is pursuing multiple mechanisms of action to tap the $4.5 billion global glaucoma market. The company is moving forward with two compounds, a dual-action Rho kinase (ROCK)  + norepinephrine transport (NET) inhibitor and a triple action ROCK+NET inhibitor + latanoprost.

    “These are both once-a-day topical products, which makes them easy for patients to use,” said Thomas Mitro, president and COO. “Both have demonstrated great safety and efficacy in clinicals. Our products can help meet the unmet medical needs in this huge marketplace.”

    Lead compound AR-13324 lowers IOP by inhibiting ROCK to enhance outflow through the trabecular meshwork and inhibiting aqueous production by inhibiting NET. Clinical trial data suggest that the compound may also lower episcleral venous pressure to enhance the overall IOP-lowering effect. The agent is effective in lowering IOP regardless of baseline pressure. Phase III trials are set for later this year.

    The second agent, P-1G324, is a fixed combination dose of AR-13324 and latanoprost. The combination of ROCK/NET inhibition plus uveoscleral outflow maximizes the potential for IOP lowering, Mitro said. A phase IIb is currently under way and data should be reported later this year.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results